-+ 0.00%
-+ 0.00%
-+ 0.00%

Bayer initiated a phase II clinical trial of an investigational inhibitor of G protein-coupled adduction potassium channel 4 in patients with atrial fibrillation.

智通財經·09/09/2026 11:49:04
語音播報
Bayer initiated a phase II clinical trial of an investigational inhibitor of G protein-coupled adduction potassium channel 4 in patients with atrial fibrillation.